Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29355884 | 0.79 | CYP1A2 (0.40) | CYP3A4CYP1A2CYP2C9CYP2C19TSHR | |
| SCHEMBL8390992 | 0.79 | KDM4E (0.45) | SLC6A4SLC6A2SLC6A3TSHRALDH1A1 | |
| SCHEMBL28190550 | 0.77 | CYP3A4 (0.44) | CYP3A4CYP1A2CYP2C9CYP2C19TSHR | |
| SCHEMBL6457239 | 0.76 | CYP3A4 (0.41) | CYP3A4CYP1A2CYP2C9CYP2C19TSHR | |
| SCHEMBL1375312 | 0.76 | CYP3A4 (0.43) | CYP3A4CYP1A2CYP2C9CYP2C19TSHR | |
| SCHEMBL6742592 | 0.76 | CYP3A4 (0.43) | CYP3A4CYP1A2CYP2C9CYP2C19TSHR | |
| SCHEMBL6737403 | 0.76 | CYP3A4 (0.43) | CYP3A4CYP1A2CYP2C9CYP2C19TSHR | |
| SCHEMBL248839 | 0.72 | ALDH1A1 (0.41) | TSHRALDH1A1MAPTKDM4E | |
| SCHEMBL27895036 | 0.72 | KDM4E (0.49) | SLC6A4SLC6A2SLC6A3TSHRALDH1A1 | |
| SCHEMBL6089703 | 0.70 | CYP3A4 (0.42) | CYP3A4CYP1A2CYP2C9CYP2C19TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE47122-E1 | 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors | EWHA University—Industry Collaboration Foundation (KR) | 2018-11-13 | — | — | US | disclosed |
| EP-2947081-B1 | 2-Pyridyl substituted imidazoles as therapeutic Alk5 and/or Alk4 inhibitors | EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUND (KR) | 2017-10-18 | — | — | EP | disclosed |
| EP-2588479-B3 | 2-PYRIDYL SUBSTITUTED IMIDAZOLES AS THERAPEUTIC ALK5 AND/OR ALK4 INHIBITORS | EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUND (KR) | 2017-03-29 | — | — | EP | disclosed |
| CN-103025731-B | 2-pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors | EWHA UNIVERSITY INDUSTRY COLLABORATION FOUNDATION (KR) | 2016-01-13 | — | — | CN | disclosed |
| EP-2947081-A1 | 2-Pyridyl substituted imidazoles as therapeutic Alk5 and/or Alk4 inhibitors | Ewha University-Industry Collaboration Foundation (KR) | 2015-11-25 | — | — | EP | disclosed |
| EP-2588479-B1 | 2-PYRIDYL SUBSTITUTED IMIDAZOLES AS THERAPEUTIC ALK5 AND/OR ALK4 INHIBITORS | UNIV EWHA IND COLLABORATION (KR) | 2015-03-04 | — | — | EP | disclosed |
| EP-2588479-A2 | 2-PYRIDYL SUBSTITUTED IMIDAZOLES AS THERAPEUTIC ALK5 AND/OR ALK4 INHIBITORS | Ewha University-Industry Collaboration Foundation (KR) | 2013-05-08 | — | — | EP | disclosed |
| CN-103025731-A | 2-pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors | UNIV EWHA IND COLLABORATION | 2013-04-03 | — | — | CN | disclosed |
| WO-2012002680-A2 | 2-PYRIDYL SUBSTITUTED IMIDAZOLES AS THERAPEUTIC ALK5 AND/OR ALK4 INHIBITORS | EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUNDATION (KR) | 2012-01-05 | — | — | WO | disclosed |
| US-20110319406-A1 | 2-PYRIDYL SUBSTITUTED IMIDAZOLES AS THERAPEUTIC ALK5 AND/OR ALK4 INHIBITORS | EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUNDATION (KR) | 2011-12-29 | — | — | US | disclosed |
| US-8080568-B1 | 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors | EWHA UNIVERSITY - INDUSTRY COLLABORATION FOUNDATION (KR) | 2011-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319406-A1 | 2-PYRIDYL SUBSTITUTED IMIDAZOLES AS THERAPEUTIC ALK5 AND/OR ALK4 INHIBITORS | ALK, ACVR1, ACVRL1 | CYP3A4 1052/4885CYP1A2 2697/4885CYP2C9 3643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.